We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule, for Alzheimer’s.
October 22, 2021
October 21, 2021
September 29, 2021
Events & Presentations
November 10, 2021 at 11:50 AM EST
October 21, 2021 at 4:30 PM EDT
April 15, 2021 at 4:30 PM EDT